

Mouse Anti-human α -macroglobulin, clone #: A04-1G3 Monoclonal Antibody

Catalog Number:	PT-mAb-A04-1G3
Quantity:	100ug
Concentration:	
Specificity:	Human
Immunogen:	Human α -macroglobulin
Isotype:	IgG
Supplies As:	Protein A purified; lyophilized
Storage:	-20 °C

Applications and Suggested Dilutions*:


Western Blot: 2 μ g/ml;
Immunohistochemistry: 2 μ g/ml

*Specific dilutions and blocking conditions should be determined by the investigator.

Reference:

Human alpha-2-macroglobulin the mAb A04-1G3

A. WB, Partially Purified Human Plasma Fractions



C. Target Verification: Proetin ID Summary

Protein Band Sliced	Protein Verified By MS/MS	Relative Abundance	UniProt Link
1	Human α -2-macroglobulin	83.8%	P01023
2	Human α -2-macroglobulin	98.4%	P01023

D. Antibody Target Verification via Proteomic Protein Identification

The amino acid sequence of human α -2-macroglobulin is retrieved from UniProt. The sequences in red are matched with peptide sequences identified by MS/MS

```

1  MGKKNKLLHPS  LVLLLLLVLLP  TDASVSGKPKQ  YMVLVPSLLH  TETTEKGCVL
51  LSYLNETVTV  SASLESVRGN  RSLFTDLEAE  NDVLCVAF  VPKSSSNEEV
111  MFLTQVQKGP  TQEFKRTTV  MVKNEDSLVF  VQTDKSIYKF  GQTVKFRVVS
161  MDENFHPLNE  LIPLVYIQDP  KGNRIAQWQS  FQLEGGLKQF  SFPLSSPEFPQ
211  GSYKVVVQKK  SGGRTHEPPT  VEEFVLKPKF  VQVTVPKIIT  ILEEE MNVSV
261  CGLYTYGKPV  PGHVTVSICR  KYSDASDCHG  EDSQAFCEKF  SGQINSHGCF
311  YQVVKTKVPQ  LKRKEYEMKL  HTEAQIQEES  TVVELTGRQS  SEITRTITKL
361  SFVKVDSHFR  QGIPFFGQVR  LVDGKGVPI  NKVIFIRGNE  ANYYSNATTD
411  EHGLVQFSIN  TTNVMGTSLT  VRVNYKDRSP  CYGYQWVSEE  HEEAHTAYL
461  VFSPSKSFVH  LEPMSHELPC  GHTQTVQAHY  ILNGGTLGL  KKL SFYLLIM
511  AKGGIVRTGT  HGLLVKQEDM  KGHFSISIPV  KSDIAPVARL  LIYAVLPTGD
561  VIGDSAKYDV  ENCLANKVDL  SFSPSQSLPA  SHAHLRVTA  PQSVCALRAV
611  DQSVLLMKPD  AELSASSVYN  LLEPKDLTGF  PGPLNDQDNE  DCINRHRVVI
661  NGITYTVPVS  TNEKDMYSFL  EDMGLKFTN  SKIRKPKMCP  QQQYEMHGF
711  EGLRVGFYES  DVMGRGHARL  VHVEEPHET  VRKYFPETWI  WDLVVVNSAG
761  VAEVGVTPD  TITEWKAGAF  CLSEDAGLGI  SSTASLRAFQ  PFFVELTMPY
811  SVIRGEAFTL  KATVLNLYPK  CIRVSVQLEA  SPAFLAVPVE  KEQAPHCICA
861  NGRQTVSWAV  TKSLGNVNF  TVSAEALESQ  ELCGTEVPSV  PEHGRKDTVI
911  KPLLVEPEGL  EKETTNSLL  CPSGGEVSEE  LSLKLPNVV  EESARASVSV
961  LGDILGSAMQ  NTQNLLQMPY  GCGEQNMVLF  APNIYVLDYL  NETQQLTPEI
1011  KSKAIGYLNT  GYQRQLNYKH  YDGSYSTFGE  RYGRNQGNTW  LTAFLKTF  A
1061  QARAYIFIDE  AHITQALIW  L  SQRQKNGCF  RSSGSLNNA  IKGVEDEV  T
1111  LSAYITIAL  L  EIPLTVTHPV  VRNALFCLES  AWKTAQEGD  H  GSHVYTKALL
1161  AYAFALAGNQ  DKRKEVLKSL  NEEAVKKNDS  VHWERPQKPK  APVGHFYE  P
1211  APSAEVEMTS  YVLLAYLTAQ  PAPTSEDLTS  ATNIVKWITK  QQNAQGGF  S
1261  TQDTVVALHA  LSKYGAATFT  RTGKAAQVTI  QSSGTFSSKF  QVDNNRLL  L
1311  QQVSLPELPG  EYSMKVTGEG  CVYLQTS LKY  NILPEKEEFP  FALGVQTL  P
1361  TCDEPKAHTS  FQISLSVSYT  GRSASNMMAI  VDVKMVS GFI  PLKPTVKM  L
1411  RSNHVSRT  EV  SSNHVLIIYLD  KVSNQTL  SLF  FTVLQDVP  VR  DLKPAIVK  VY
1461  DYYETDEF  AI  AEYNAPCSR  D  LGNA
  
```

B. Immunoaffinity Purification

